KOSDAQBiotech & Pharma389030

Geninus

₩1,295▲ 1.33%2026-11-18 close
Market Cap
₩51B
Turnover
₩700M
Volume
560K
Shares out.
39.4M
PER
—
PBR
1.2×
EPS
-₩615
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue Recovering Amid Losses; Japan and Pharma Deals in Focus

Geninus lifted 2025 sales to KRW 10.5 billion, but operating losses of KRW 11.7 billion kept the company in the red, and the third-quarter 2026 operating loss of KRW 3.24 billion widened from a year earlier.

  1. 1

    Sales rose 62.4% year on year in 2025, making it the largest year among 2022 to 2025, while 2024 was the smallest.

  2. 2

    The net loss attributable to controlling shareholders widened to KRW 17.4 billion in 2025 from KRW 12.3 billion in 2024. In the fourth quarter of 2025, that loss of KRW 8.13 billion was well above the operating loss of KRW 2.96 billion, meaning items below operating profit added to the deficit.

  3. 3

    Third-quarter 2026 sales of KRW 2.29 billion rose 6.3% from a year earlier, yet the operating loss of KRW 3.24 billion was larger than the KRW 2.33 billion posted a year earlier.

  4. 4

    Sales of KRW 10.5 billion in 2025 fell short of the KRW 14.5 billion target the company set for that year, and the gap to the KRW 21 billion target for 2026 is the next thing to check.

  5. 5

    Total liabilities of KRW 30.2 billion at the end of 2025 far exceeded total equity of KRW 9.1 billion, with a debt ratio of 332.3%; equity changes and cash flow are the next items to watch.

02

Business structure

Geninus is a genomics analysis company founded in 2018. The company says it is shrinking its NGS (next-generation sequencing) based genomic analysis work and shifting weight toward drug-discovery solutions that combine single-cell and spatial transcriptomics (spatial omics) analysis with AI.

The business falls into three lines. The first is data and analysis services for drug developers, with a contract reportedly signed with a large domestic pharmaceutical company and follow-on contract talks reported to be ongoing.

The second is clinical trial sample analysis as a contract research organization (CRO); in November 2024 the company was designated a GCLP-compliant clinical sample analysis institution by the Ministry of Food and Drug Safety. The third is Japan.

Its subsidiary GxD, established in July 2023, joined the SCRUM Japan project led by the National Cancer Center Japan and provides single-cell and spatial transcriptomics analysis, and the company has said the project secured roughly KRW 10 billion in sales over three years.

In March 2026, reports cited the company's statement that it met the high quality standards and operating requirements of a Japanese pharmaceutical company.

On data assets, the company says joint research with Samsung Medical Center and the National Cancer Center Japan Hospital has secured about 60,000 single-cell and spatial transcriptomics records. Customers include large domestic pharmaceutical companies, biotech firms and Japanese pharmaceutical companies.

Competitively, the company claims the top position in Korea's single-cell and spatial transcriptomics analysis market and cites overseas AI data companies such as Tempus AI and Owkin as reference models. The largest shareholder is CEO Park Woong-yang, with a 30.88% stake as of December 31, 2024.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩2.2B-₩2.3B−108.3%
2025Q4₩3.1B-₩3B−94.3%
2026Q1₩2.4B-₩2B−85.8%
2026Q2₩3.6B-₩4.6B−127.4%
2026Q3₩2.3B-₩3.2B−141.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩10.1B-₩9.7B-₩9.4B−96.0%−21.7%5.9%
2023₩7B-₩10.1B-₩9.7B−144.7%−28.1%17.5%
2024₩6.5B-₩12.3B-₩12.3B−189.9%−55.2%48.8%
2025₩10.5B-₩11.7B-₩17.4B−111.3%−190.9%332.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On a disclosed basis, sales were KRW 10.1 billion in 2022, KRW 6.97 billion in 2023, KRW 6.46 billion in 2024 and KRW 10.5 billion in 2025. Sales fell 30.9% in 2023 and 7.3% in 2024, which made 2024 the smallest year of 2022 to 2025. Sales rose 62.4% in 2025, which made it the largest year.

Operating losses over the same period were KRW 9.68 billion, KRW 10.1 billion, KRW 12.3 billion and KRW 11.7 billion. The deficit widened in 2023 and 2024 and narrowed in 2025. Operating margins were -96.0%, -144.7%, -189.9% and -111.3%, with 2024 the most negative.

For 2024, the company attributed the weak results to intensifying competition in genomic analysis, continued R&D spending and general economic uncertainty.

The net loss attributable to controlling shareholders was KRW 9.38 billion, KRW 9.68 billion, KRW 12.3 billion and KRW 17.4 billion, a loss in each of the four years from 2022 to 2025, with 2025 the largest. The net loss including non-controlling interests was reported at the same levels.

Operating cash flow was -KRW 12 billion, -KRW 8.13 billion, -KRW 10.7 billion and -KRW 7.08 billion, with the 2025 outflow the smallest. The debt ratio climbed from 5.9% to 17.5%, 48.8% and then 332.3%.

Quarterly sales are volatile: KRW 2.15 billion in the third quarter of 2025, KRW 3.13 billion in the fourth quarter (up 45.7% from the prior quarter), KRW 2.39 billion in the first quarter of 2026 (down 23.9%), KRW 3.61 billion in the second quarter (up 51.2%) and KRW 2.29 billion in the third quarter (down 36.6%).

Third-quarter 2026 sales were up 6.3% from a year earlier. The operating loss was KRW 2.33 billion, KRW 2.96 billion, KRW 2.05 billion, KRW 4.59 billion and KRW 3.24 billion across the same five quarters, with the second quarter of 2026 the largest loss of the five.

The net loss attributable to controlling shareholders was KRW 2.45 billion, KRW 8.13 billion, KRW 2.03 billion, KRW 7.75 billion and KRW 3.7 billion, a loss in all five quarters. The last four quarters together total KRW 21.6 billion.

05

Industry analysis

The single-cell and spatial transcriptomics demand the company emphasizes is spreading from early-stage target discovery into clinical trial design.

The company's argument starts from the view that global big pharma, including Roche, is using single-cell and spatial omics to raise the odds of drug development success and shorten timelines.

The company also argues that demand for spatial omics solutions grows as competition in antibody-drug conjugate (ADC) development intensifies, and that the many ADC developers widen opportunities for partnerships with drugmakers.

In contrast, the conventional genomic analysis market is highly competitive, which was cited as one reason for weak 2024 results.

Domestically, the company claims the top position in single-cell and spatial transcriptomics analysis and cites a 75% share of the domestic spatial transcriptomics market; this is the company's own claim and should be read separately from third-party market statistics.

Overseas, Tempus AI is cited as an example of a large genomic data business, and Owkin is referenced as a model for AI-based single-cell and spatial transcriptomics services. Reports also describe rising investment by domestic and global biotech and pharmaceutical companies in AI-driven drug discovery.

Data on where the industry sits in its cycle were not available in the sources, so demand signals are best read through the number of large pharma contracts and announced collaborations with global big pharma.

06

Outlook

The company's targets are sales of KRW 21 billion and an operating loss of KRW 4 billion for 2026, and sales of KRW 31 billion and an operating profit of KRW 1 billion for 2027. These figures came from the restructuring plan laid out in 2025.

Because 2025 sales of KRW 10.5 billion fell short of the KRW 14.5 billion target set that year, the path to the new targets matters. Press reports citing the quarterly filings put cumulative January-to-September 2026 sales at KRW 8.3 billion and the cumulative operating loss at KRW 9.9 billion.

Reaching the 2026 sales target of KRW 21 billion would require about KRW 12.7 billion in the fourth quarter, a large gap. The cumulative operating loss through September already exceeds the 2026 operating loss target of KRW 4 billion.

In March 2026 the company said it expects sales at its Japanese subsidiary GxD to rise more than 80% in 2026. In a 2025 interview, the CEO said the Japan business should reach break-even in 2026, and that break-even including domestic operations is achievable in 2027.

The same interview expected a large deal with a global big pharma company in the second half of 2026. The US market entry was set as a 2026 goal. All of these timelines rest on company statements, and the size and timing of contracts should be confirmed through disclosures.

07

Valuation

PER
—
PBR
1.2×
ROE
-85.1%
EPS
-₩615
BPS
₩1,038
Dividend per share
₩0

Because the last four quarters include net losses attributable to controlling shareholders, the earnings-based PER cannot be calculated. With no profit base to anchor the share price, valuation rests more on assets and business indicators. The price-to-book ratio sits at a premium to net asset value.

However, total equity was KRW 9.1 billion at the end of 2025, which is far below the market capitalization scale, so changes in equity during 2026, such as rights issues or conversion of convertible bonds, need to be checked before the price-to-book ratio can be read accurately.

In May 2025, a Korea Investment Partners-led consortium was reported to have invested KRW 10 billion in convertible bonds. Dividends have not been sustained through the loss years, so shareholder return provides a weak basis for valuation.

Because earnings-based peer comparisons are not meaningful for a loss-making company, comparisons with listed biopharma peers are closer to revenue growth and pipeline scale. Reports have shown the share price moving sharply on contract and Japan-sales news, which also shapes how the valuation is read.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Larger revenue base

Sales reached KRW 10.5 billion in 2025, up 62.4% and the largest year of 2022 to 2025. Third-quarter 2026 sales of KRW 2.29 billion were up 6.3% from a year earlier. Cumulative January-to-September 2026 sales were reported at KRW 8.3 billion, extending the growth trend.

Japan business growth path

The company says its Japanese subsidiary GxD secured roughly KRW 10 billion in sales over three years through the SCRUM Japan project. In March 2026 the company expected GxD's 2026 sales to rise more than 80%. The company argues that a larger Japan share could reduce reliance on the lumpy domestic pharma contracts.

Single-cell and spatial omics demand

Reports describe global big pharma using single-cell and spatial omics in drug development. The company argues that growing ADC development expands demand for spatial omics analysis. It cites its domestic market position and a data asset of about 60,000 records as strengths.

09

Bear factors

Persistent losses and volatile quarters

The net loss attributable to controlling shareholders has been a loss in each year from 2022 to 2025, and was largest in 2025 at KRW 17.4 billion.

The second-quarter 2026 operating loss of KRW 4.59 billion was the largest of the last five quarters, and the third-quarter loss of KRW 3.24 billion widened from a year earlier.

The cumulative operating loss through September 2026 of about KRW 9.9 billion already exceeds the KRW 4 billion operating loss target for the full year.

Financial strain and capital structure

At the end of 2025, total liabilities were KRW 30.2 billion against total equity of KRW 9.1 billion, a debt ratio of 332.3%. Operating cash flow has been negative in each year from 2022 to 2025, at -KRW 7.08 billion in 2025.

The KRW 10 billion convertible bond investment reported in May 2025 could affect the capital structure if converted into shares.

Gap between targets and results

The company set a 2025 sales target of KRW 14.5 billion but reported KRW 10.5 billion. Reaching the 2026 target of KRW 21 billion would require roughly KRW 12.7 billion in the fourth quarter alone.

Intensifying competition in genomic analysis was cited as a reason for weak results, so whether the restructuring delivers at the targeted scale is the key test.

10

Risk factors

Contract concentration risk

Sales depend heavily on a small number of large pharma contracts and the Japan project. An industry source reported that the initial domestic pharma contract was worth KRW 500 million or less, and follow-on contract sizes have not been disclosed. Quarterly sales can swing sharply depending on the timing and size of individual contracts.

Financial and capital risk

A 2025 report said cash of about KRW 16 billion at the end of the first half of 2025 would fund operations into mid-2026 without new financing. With cumulative operating losses of about KRW 9.9 billion reported for January to September 2026, that runway assumption may no longer hold. Conversion of bonds or new share issuance could dilute existing shareholders.

Execution risk of the business shift

The company is shrinking its NGS-based genomic analysis business in favor of a single-cell and spatial omics drug-discovery platform. Past sales targets were set well above results, so the realism of new revenue plans needs to be tested. Entry into Japan and the US may slip depending on regulation and local partner terms.

11

What to watch next

  1. By end of December 2026

    Whether the large deal with a global big pharma company that the company flagged for the second half of 2026, the 2026 US entry target and the GxD sales growth outlook of more than 80% are realized. Confirmation through disclosures is the key test.

  2. Around the end of March 2027 (annual report filing deadline)

    Annual 2026 sales and operating loss in the annual report, achievement against the KRW 21 billion sales target, operating cash flow, and equity changes including any bond conversion or share issuance.

  3. Early 2027 (check company disclosure schedule)

    When fourth-quarter 2026 results are disclosed, whether fourth-quarter sales approach the roughly KRW 12.7 billion needed to reach the annual target, and how the cumulative operating loss trend closes.

  4. At 2027 full-year results (per company targets)

    Whether 2027 sales reach KRW 31 billion and operating profit reaches KRW 1 billion, and whether break-even is achieved including domestic operations. Whether earnings turn positive in 2027 is the most direct test of the business shift.

12

Overall view

Geninus recorded its largest sales year of 2022 to 2025 in 2025 at KRW 10.5 billion, but the operating loss of KRW 11.7 billion and the net loss attributable to controlling shareholders of KRW 17.4 billion kept the loss-making structure in place.

Third-quarter 2026 sales of KRW 2.29 billion rose from a year earlier, while the operating loss of KRW 3.24 billion widened.

Growth drivers cited include sales expansion at the Japanese subsidiary GxD, contracts with large domestic pharmaceutical companies, and rising demand for single-cell and spatial transcriptomics analysis.

On the other side, the gap between results and targets, volatile quarterly profit and loss, and financial strain from a debt ratio of 332.3% and total liabilities of KRW 30.2 billion remain weak points. Neither the bullish nor the bearish factors clearly dominate at this stage.

The next checkpoints are annual sales and operating loss in the 2026 annual report, equity changes, and whether the 2027 break-even target is met. Until then, quarterly sales swings and the size of disclosed contracts are the items to track.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. vegannews.co.kr
  2. core.asiae.co.kr
  3. hankyung.com
  4. whosaeng.com
  5. pinpointnews.co.kr
  6. hitnews.co.kr
  7. paxetv.com
  8. paxetv.com
  9. pharm.edaily.co.kr
  10. businesspost.co.kr
  11. comp.fnguide.com
  12. tradingkey.com
  13. boannews.com
  14. tradingkey.com
  15. denews.co.kr
  16. dailysecu.com
  17. tradingkey.com
  18. supple.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis